ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

dapagliflozin

Also written as “Dapagliflozin”, “Dapagliflozin 10 mg” and “Dapagliflozin 10mg”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Renal Insufficiency, Chronic · Heart Failure · Diabetes Mellitus · Diabetes Mellitus, Type 1, led by 14 companies.

Drug pageDapagliflozin: every studyMany companies study it; this page follows only the 131 they lead. All 485 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jun 2, 2014131 company-led studies, 13 open or runningNext primary completion: Dec 10, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZenecaits history only10910 open or runningphase 4since Jun 2, 2014Sep 9, 2005Dec 10, 2026phase 2 · NCT07222917
LG Chemits history only60 open or runningphase 3since Feb 2, 2020May 24, 2018none ahead
Boryung Pharmaceuticalits history only32 open or runningphase 1since May 26, 2022May 26, 2022none ahead
Dong-A STits history only20 open or runningphase 3since Apr 20, 2020Dec 5, 2018none ahead
Hansoh Pharmaceutical Groupits history only20 open or runningphase 1since Apr 30, 2021Apr 30, 2021none ahead
autotelicbioits history only10 open or runningphase 1since Apr 20, 2021Apr 20, 2021none ahead
Daewoong Pharmaceuticalits history only10 open or runningphase 3since Nov 12, 2020Nov 12, 2020none ahead
Dexa Medica Groupits history only10 open or runningno phasesince Nov 7, 2023Nov 7, 2023none ahead
dong-wha-pharmaceutical-co-ltdits history only10 open or runningphase 1since May 4, 2022May 4, 2022none ahead
George Clinical Ptyits history only10 open or runningphase 4since Nov 3, 2020Nov 3, 2020none ahead
thpharm-corp10 open or runningphase 1since Sep 8, 2023Sep 8, 2023none ahead
  • Named in AstraZeneca’s own pipeline as zibotentan/dapagliflozin, phase 3, as of Oct 30, 2026 (source).

Also a collaborator on its studies: Fortrea, Parexel, Ground Zero Pharmaceuticals, PT Equilab International, Bristol-Myers Squibb, Q2 Solutions, PRA Health Sciences, Covance and Antaros Medical.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of thpharm-corp only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 8, 2023First study: phase 1 study in HypertensionFirst studyNCT06063109 · 51 enrolled · South Korea

TargetBeta

“The propanediol form of dapagliflozin, a selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor with antihyperglycemic activity. Upon administration, dapagliflozin selectively targets and inhibits SGLT2, thereby preventing the reabsorption of glucose by the kidneys.”NCIt, read by Claude
“The propanediol form of dapagliflozin, a selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor with antihyperglycemic activity”NCIt, by rule
“Sodium/glucose cotransporter 2 inhibitor; Sodium/glucose cotransporter 2 inhibitor”ChEMBL 37, by rule

Other programs on SLC5A2

ProgramCompanyFurthest phaseStudies
empagliflozinruleBoehringer Ingelheimphase 4142
ertugliflozinruleMerckphase 422
EnavogliflozinruleDaewoong Pharmaceuticalphase 325
vicadrostatBoehringer Ingelheimphase 316
Empagliflozin/LinagliptinruleHumanis Saglık Anonim Sirketiphase 12

Studies

The one study thpharm-corp leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06063109Hypertension · South Korea1CompletedNov 9, 202351

How it is read

Names in the registry

  • “Dapagliflozin”, 90 entries
  • “dapagliflozin”, 18 entries
  • “Dapagliflozin 10 mg”, 6 entries
  • “Dapagliflozin 10mg”, 5 entries
  • “Dapagliflozin/metformin XR 10/1000mg”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.